29 Outcomes of resected SST after CRT Table 4. Number of patients with tumour response based on pre and post CRT imaging using RECIST criteria, and a comparison of pre-CRT imaging and post CRT gross pathology. The number of patients in these groups with pathologic complete response (pCR) is also described. RECIST (Number; %) (Pathologic Complete Response: Number; %) Partial Response Stable Disease Progressive disease Missing Total Pre – post- CRT imaging 14; 30% (10; 50%) 29; 63% (7; 35%) 0 3; 7% (3; 15%) 46 (20; 100%) Pre-CRT imaging – postCRT gross pathology 27; 59% (16; 80%) 15; 33% (3; 15%) 4; 9% (1; 5%) 0 46 (20; 100%) CRT chemoradiotherapy Follow-up data Follow-up data was available for all patients. There were no differences in follow-up status between the two hospitals or between patients with different clinical stages. Table 5 shows the follow-up status of all eligible patients according to tumour type and tumour response. Table 5. Follow up status related to tumour type and pathological response Follow up status AND DND AWD DOD Tumour type Squamous cell carcinoma 2 1 0 4 Adenocarcinoma 8 2 1 10 Large cell carcinoma 6 1 0 7 Unknown 2 0 0 2 Total 18 4 1 23 Tumour response Complete regression 12 1 1 6 < 10% vital tumour 1 0 0 2 10-50% vital tumour 3 3 0 11 >50% vital tumour 1 0 0 4 Total 18 4 1 23 AND = Alive No Disease; DND = Dead No Disease; AWD = Alive With Disease; DOD = Dead Of Disease The median follow-up time was 34 months (range 5 – 154 months). Prognosis was significantly better after a pCR compared to residual tumour (70% 5-years overall survival vs. 20%; p=0.001) and in patients with fewer than 10% vital tumour cells as compared to those with >10% (65% 5-years overall survival vs 18%; p<0.001; Figure 2
RkJQdWJsaXNoZXIy MTk4NDMw